Predictive tissue biomarkers for bevacizumab-containing therapy in metastatic colorectal cancer Vrije Universiteit Brussel Universiteit Antwerpen
Bevacizumab is the first anti-angiogenic agent approved for the treatment of metastatic colorectal cancer. The need for patient selection before initiating therapy necessitates the study of various proteins expressed in metastatic colorectal cancer tissue as candidate predictive markers. Immunohistochemistry is a valuable, commonly available and cost-effective method to assess predictive biomarkers. However, it is subject to variations and ...